Skip to main content

8110 Gatehouse Road, Falls Church, VA 22042

Adam L. Cohen, MD

A member of Inova Medical Group
The doctors of Inova Medical Group are Inova’s premier primary care and specialty physicians, offering top-notch medical expertise, full access to Inova facilities, and the convenience of integrated electronic medical records.
Adam Cohen, MD

Specialty

Board-certified specialties granted by an ABMS Member Board. Learn more about board certification.
Medical Oncology, Internal Medicine

Clinical Interest

Areas of special interest identified by the physician or additional training completed.
Brain Cancer/Tumors, Cancer, Spine tumor

Years of Experience

16

Gender

Male

Languages

English
Request Profile Update
Translate

About Adam Cohen, MD

Dr. Adam L. Cohen is a specialty care physician board certified in neuro-oncology, medical oncology and internal medicine. He received his MS from the University of Chicago and MD from Harvard Medical School. He completed internal medicine residency at Banner Good Samaritan Medical Center in Phoenix, Arizona, and medical oncology fellowship at Huntsman Cancer Institute, University of Utah. He joined Inova Health System in 2020 and has been practicing since 2011. He specializes in primary and metastatic cancers of the central nervous system and serves as the Co-Director of the Neuro-Oncology program at the Inova Schar Cancer Institute.

Prior to joining Inova, Dr. Cohen worked as an Associate Professor at the Huntsman Cancer Institute in Salt Lake City, UT. He is married to a genetic counselor and has four children. He enjoys crossword puzzles, knitting, and science fiction.

Memberships/Accreditations

  • Member, American Society of Clinical Oncology
  • Member, Society for Neuro-Oncology
  • Member, American Association for Neurology

Publications

Cohen, AL, Anker, CJ, Johnson, B, Burt, LM, Shrieve, DC, Salzman, K, Jensen, R, Boucher, K, Colman, H (2020). Repeat radiation with bevacizumab and minocycline in bevacizumab-refractory high grade gliomas: a prospective phase 1 trial. Journal of neuro-oncology, 148(3), 577–585.

Smith-Cohn M, Davidson C, Colman H, Cohen AL (2019). Challenges of targeting BRAF V600E mutations in adult primary brain tumor patients: a report of two cases. CNS Oncol, 8(4), CNS48.

Huang J, Chaudhary R, Cohen AL, Fink K, Goldlust S, Boockvar J, Chinnaiyan P, Wan L, Marcus S, Campian JL (2019). A multicenter phase II study of temozolomide plus disulfiram and copper for recurrent temozolomide-resistant glioblastoma. J Neurooncol, 142(3), 537-544.

Hummel S, Kohlmann W, Kollmeyer TM, Jenkins R, Sonnen J, Palmer CA, Colman H, Abbott D, Cannon-Albright L, Cohen AL (2019). The contribution of the rs55705857 G allele to familial cancer risk as estimated in the Utah population database. BMC Cancer, 19(1), 190.

Cloughesy TF, Mochizuki AY, Orpilla JR, Hugo W, Lee AH, Davidson TB, Wang AC, Ellingson BM, Rytlewski JA, Sanders CM, Kawaguchi ES, Du L, Li G, Yong WH, Gaffey SC, Cohen AL, Mellinghoff IK, Lee EQ, Reardon DA, O'Brien BJ, Butowski NA, Nghiemphu PL, Clarke JL, Arrillaga-Romany IC, Colman H, Kaley TJ, de Groot JF, Liau LM, Wen PY, Prins RM (2019). Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma. Nat Med, 25(3), 477-486.

Frandsen J, Orton A, Jensen R, Colman H, Cohen AL, Tward J, Shrieve DC, Suneja G (2018). Patterns of care and outcomes in gliosarcoma: an analysis of the National Cancer Database. J Neurosurg, 128(4), 1133-1138.

Brady SW, McQuerry JA, Qiao Y, Piccolo SR, Shrestha G, Jenkins DF, Layer RM, Pedersen BS, Miller RH, Esch A, Selitsky SR, Parker JS, Anderson LA, Dalley BK, Factor RE, Reddy CB, Boltax JP, Li DY, Moos PJ, Gray JW, Heiser LM, Buys SS, Cohen AL, Johnson WE, Quinlan AR, Marth G, Werner TL, Bild AH (2017). Combating subclonal evolution of resistant cancer phenotypes. Nat Commun, 8(1), 1231.

Reblin M, Wu YP, Pok J, Kane L, Colman H, Cohen AL, Mendivil E, Warner EL, Meyer M, Agutter J (2017). Development of the Electronic Social Network Assessment Program Using the Center for eHealth and Wellbeing Research Roadmap. JMIR Hum Factors, 4(3), e23.

Cohen AL, Ray A, Van Brocklin M, Burnett DM, Bowen RC, Dyess DL, Butler TW, Dumlao T, Khong HT (2017). A phase I trial of azacitidine and nanoparticle albumin bound paclitaxel in patients with advanced or metastatic solid tumors. Oncotarget, 8(32), 52413-52419.

Gardner LJ, Ward M, Andtbacka RHI, Boucher KM, Bowen GM, Bowles TL, Cohen AL, Grossmann K, Hitchcock YJ, Holmen SL, Hyngstrom J, Khong H, McMahon M, Monroe MM, Ross CB, Suneja G, Wada D, Grossman D (2017). Risk factors for development of melanoma brain metastasis and disease progression: a single-center retrospective analysis. Melanoma Res, 27(5), 477-484.

Gardner LJ, Ward M, Andtbacka RHI, Boucher KM, Bowen GM, Bowles TL, Cohen AL, Grossmann K, Hitchcock YJ, Holmen SL, Hyngstrom J, Khong H, McMahon M, Monroe MM, Ross CB, Suneja G, Wada D, Grossman D (2017). Risk factors for development of melanoma brain metastasis and disease progression: a single-center retrospective analysis. Melanoma Res, 27(5), 477-484.

Werner TL, Ray A, Lamb JG, VanBrocklin M, Hueftle K, Cohen AL, Beck AC, Buys SS, Dyess DL, Butler TW, Dumlao TL, Neumayer L, Khong HT (2017). A Phase I Study of Neoadjuvant Chemotherapy With Nab-Paclitaxel, Doxorubicin, and Cyclophosphamide in Patients With Stage II to III Breast Cancer. Clin Breast Cancer, 17(7), 503-509.

Thomson N, Pacak K, Schmidt MH, Palmer CA, Salzman KL, Champine M, Schiffman JD, Cohen AL (2017). Leptomeningeal dissemination of a low-grade lumbar paraganglioma: case report. J Neurosurg Spine, 26(4), 501-506.

Thomson N, Pacak K, Schmidt MH, Palmer CA, Salzman KL, Champine M, Schiffman JD, Cohen AL (2017). Leptomeningeal dissemination of a low-grade lumbar paraganglioma: case report. J Neurosurg Spine, 26(4), 501-506.

Cohen AL, Factor RE, Mooney K, Salama ME, Wade M, Serpico V, Ostrander E, Nelson E, Porretta J, Matsen C, Bernard P, Boucher K, Neumayer L (2017). POWERPIINC (PreOperative Window of Endocrine TheRapy Provides Information to Increase Compliance) trial: Changes in tumor proliferation index and quality of life with 7 days of preoperative tamoxifen. Breast, 31, 219-223.

Huang LE, Cohen AL, Colman H, Jensen RL, Fults DW, Couldwell WT (2017). IGFBP2 expression predicts IDH-mutant glioma patient survival. Oncotarget, 8(1), 191-202.

Cohen AL, Neumayer L, Boucher K, Factor RE, Shrestha G, Wade M, Lamb JG, Arbogast K, Piccolo SR, Riegert J, Schabel M, Bild AH, Werner TL (04/2017). Window-of-Opportunity Study of Valproic Acid in Breast Cancer Testing a Gene Expression Biomarker. JCO Precis Oncol, 1 (April 2017), 1-11.

Cohen AL, Ray A, Van Brocklin M, Burnett DM, Bowen RC, Dyess DL, Butler TW, Dumlao T, Khong HT (2016). A phase I trial of azacitidine and nanoparticle albumin bound paclitaxel in patients with advanced or metastatic solid tumors. [Epub ahead of print]. Oncotarget.

Piccolo SR, Hoffman LM, Conner T, Shrestha G, Cohen AL, Marks JR, Neumayer LA, Agarwal CA, Beckerle MC, Andrulis IL, Spira AE, Moos PJ, Buys SS, Johnson WE, Bild AH (2016). Integrative analyses reveal signaling pathways underlying familial breast cancer susceptibility. Mol Syst Biol, 12(3), 860.

Piccolo SR, Hoffman LM, Conner T, Shrestha G, Cohen AL, Marks JR, Neurmayer LA, Agarwal CA, Beckerle MC, Andrulis IL, Spira AK, Moos PJ, Buys SS, Johnson WE, Bild AH (2016). Integrative analyses reveal signaling pathways underlying familial breast cancer susceptibility. Mol Syst Biol, 12(3), 860.

Piccolo SR, Andrulis IL, Cohen AL, Conner T, Moos PJ, Spira AE, Buys SS, Johnson WE, Bild AH (2015). Gene-expression patterns in peripheral blood classify familial breast cancer susceptibility. BMC Med Genomics, 8, 72.

Cohen A, Sato M, Aldape K, Mason CC, Alfaro-Munoz K, et al. (2015). DNA copy number analysis of Grade II-III and Grade IV gliomas reveals differences in molecular ontogeny including chromothripsis associated with IDH mutation status. Acta Neuropathol Commun, 2015(3), 34.

Shen L, O'Shea JM, Kaadige MR, Cunha S, Wilde BR, Cohen AL, Welm AL, Ayer DE. (2015). Metabolic reprogramming in triple-negative breast cancer through Myc suppression of TXNIP. Proc Natl Acad Sci U S A, 112(17), 5425-30.

El-Chaar NN, Piccolo SR, Boucher KM, Cohen AL, Chang JT, Moos PJ, Bild AH (2014). Genomic classification of the RAS network identifies a personalized treatment strategy for lung cancer. Mol Oncol, 8(7), 1339-54.

Zhang H, Cohen AL, Krishnakumar S, Wapnir IL, Veeriah S, Deng G, Coram MA, Piskun CM, Longacre TA, Herrler M, Frimannsson DO, Telli ML, Dirbas FM, Matin AC, Dairkee SH, Larijani B, Glinsky GV, Bild AH, Jeffrey SS (2014). Patient-derived xenografts of triple-negative breast cancer reproduce molecular features of patient tumors and respond to mTOR inhibition. Breast Cancer Res, 16(2), R36.

Cohen AL, Piccolo SR, Cheng L, Soldi R, Han B, Johnson WE, Bild AH (2013). Genomic pathway analysis reveals that EZH2 and HDAC4 represent mutually exclusive epigenetic pathways across human cancers. BMC Med Genomics, 6, 35.

Soldi R, Cohen AL, Cheng L, Sun Y, Moos PJ, Bild AH (2013). A genomic approach to predict synergistic combinations for breast cancer treatment. Pharmacogenomics J, 13(1), 94-104.

Cohen AL, Salzman K, Palmer C, Jensen R, Colman H (2013). Bevacizumab is Effective for Recurrent Papillary Tumor of the Pineal Region: First Report. Case Rep Oncol, 6(2), 434-40.

Cohen AL, Soldi R, Zhang H, Gustafson AM, Wilcox R, Welm BE, Chang JT, Johnson E, Spira A, Jeffrey SS, Bild AH (2011). A pharmacogenomic method for individualized prediction of drug sensitivity. Mol Syst Biol, 7, 513.

Cohen AL, Ward JH (2010). Risk reduction strategies for ductal carcinoma in situ. J Natl Compr Canc Netw, 8(10), 1211-7.

Cohen AL, Sarid R (2010). The relationship between monoclonal gammopathy of undetermined significance and venous thromboembolic disease. Thromb Res, 125(3), 216-9.

Cohen AL, Rodman L, Stanford DP (1999). Pointwise and Uniformly Convergent Sets of Matrices. SIAM J Appl Math, 21(1), 93-105.

Background

Medical Education

Harvard Medical School 2004

Residency

Banner Good Samaritan Medical Center
Training Specialty: Internal Medicine
6/23/2004 - 06/30/2008

Fellowships

University of Utah
Training Specialty: Medical Oncology
07/01/2008 - 06/30/2011

Board Certification

Medical Oncology, Internal Medicine

Hospital Affliation

Patient Reviews

About Patient Comments

The Patient Rating score is an average of all responses to physician related questions on our nationally-recognized Press Ganey Patient Satisfaction Survey. Responses are measured on a scale of 1 to 5, with 5 being the best score. Comments are gathered from our Press Ganey Patient Satisfaction Survey and displayed in their entirety. Patients are de-identified for confidentiality and patient privacy.

Learn More

Inova Physician Referral Services

Please make note of the following information.

This referral service is sponsored by Inova. Only physicians with appropriate medical staff privileges at an Inova affiliated hospital may participate. There is no charge or fee to you or for the participating physician for our service. Physician participation is voluntary.

Physician referrals will be based on your referral needs and preferences of location, specialty, and rotation availability of the physician.

The physicians on our referral panel are independent practitioners or physician employees. The independent practitioners are not employees, agents or representatives of Inova and are solely responsible for their provision of medical care to you.